Qritive, Corista tie up for digital pathology integration


Singapore-headquartered Qritive has integrated its AI modules with US-based Corista’s image management platform DP3. 

According to a press statement, the combined solution leverages AI to screen for both prostate and colon cancers, quantify IHC markers, and detect lymph node metastasis. 

It allows pathologists to prioritise and grade specific cases while improving the detection of hard-to-diagnose cancers. It also enables pre-reviewed AI analysis of digital pathology images utilising any whole slide image scanning device and LIS.

Corista’s DP3 is a DICOM-compliant pathology software that enables voice collaborations, remote case reviews, and global consults. It can integrate with either in-house or commercially available image analysis systems and features a proprietary LIS Connector. 


Pathology departments have been overwhelmed with huge demands for diagnostic screening which rose with a rapidly ageing population, a growing incidence of chronic diseases, and the emergence of various epidemics.

Integrating AI into pathology workflow has the potential to raise pathologists’ efficiency. It delivers high-quality diagnoses while helping free up pathologists’ time to focus on more complex cases. 

“Our partnership with Qritive will advance the use of [AI] applications to support the growing demands on pathologists to keep up with the pace of their workloads and the challenges of cancer diagnosis,” said Liz Wingard, CEO and co-founder of Corista. 

“Corista’s image management system combined with the assistive power of Qritive’s AI modules is the ideal workbench for pathologists to conduct diagnostics with ease, consistency, and precision,” Qritive CEO and co-founder Aneesh Sathe claimed.


In the same week, Qritive also announced the launch of its latest AI module for prostate cancer diagnosis. Called QAi Prostrate, the software module analyses whole slide images of prostate core needle biopsies, identifies prostatic adenocarcinoma region, and segments and classifies them into benign and malignant areas. It also provides a detailed summary explaining the tumour size and percentage for each slide or region of interest. The module can be integrated with any standard digital pathology system, as well as with existing workflows using an open API interface through customisable middleware.

At the start of the year, Qritive raised $7.5 million in a funding round, which was intended to support its global expansion, regulatory approval attempts, and development of more AI imaging analysis solutions.

Source link

Leave A Reply
0 0